Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0190-9622(08)80203-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recalcitrant Female Pattern Hair Loss Like Alopecia Unveils Unexpected Rare Entity.
Clin Cosmet Investig Dermatol
January 2025
Lugansk state medical University, Department of Pathology, Rivne, Ukraine.
Introduction: Marie-Unna hereditary hypotrichosis (MUHH) is an autosomal dominant disorder characterized by a specific pattern of hair loss. Initially described in 1925 by Marie-Unna in a German family spanning over seven generations, MUHH represents a previously unidentified form of congenital hypotrichosis. It typically presents as sparse hair at birth with a coarse texture, followed by regrowth during childhood then, finally, gradual hair loss at puberty, resembling pattern of androgenetic alopecia.
View Article and Find Full Text PDFLocal Hyperthermia Combined With Imiquimod Cleared Recalcitrant and Extensive Warts in a Patient With Systemic Lupus Erythematosus.
Clin Cosmet Investig Dermatol
January 2025
Department of Dermatology, the First Hospital of China Medical University, Shenyang, Liaoning Province, People's Republic of China.
Viral warts, a common dermatological condition caused by human papillomavirus infection (HPV) infection, present a particular challenge for systemic lupus erythematosus (SLE) patients due to their compromised immunity, which increases the susceptibility to HPV infection and complicates treatment efforts. Imiquimod, an immunomodulatory agent, has demonstrated efficacy in managing warts. Furthermore, local hyperthermia, a non-invasive therapeutic modality, has demonstrated significant potential in the management of warts.
View Article and Find Full Text PDFDual immunomodulator therapy with adalimumab and upadacitinib to treat recalcitrant hidradenitis suppurativa.
JAAD Case Rep
February 2025
Division of Dermatology, Albert Einstein College of Medicine, Bronx, New York.
A safe haven for cancer cells: tumor plus stroma control by DYRK1B.
Oncogene
January 2025
Department of Gastroenterology, Endocrinology and Metabolism, Center for Tumor and Immune Biology, Philipps University Marburg, Marburg, Germany.
The development of resistance remains one of the biggest challenges in clinical cancer patient care and it comprises all treatment modalities from chemotherapy to targeted or immune therapy. In solid malignancies, drug resistance is the result of adaptive processes occurring in cancer cells or the surrounding tumor microenvironment (TME). Future therapy attempts will therefore benefit from targeting both, tumor and stroma compartments and drug targets which affect both sides will be highly appreciated.
View Article and Find Full Text PDFAnalysis of quantitative OCT and SS-OCTA metrics three months after initiation of intravitreal faricimab for treatment-recalcitrant neovascular AMD.
Eye (Lond)
January 2025
Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Purpose: To utilize optical coherence tomography (OCT) and SS-OCT angiography (SS-OCTA) for quantifying morphological changes seen in eyes with recalcitrant neovascular age-related macular degeneration (nAMD) transitioned to intravitreal faricimab injections during the manufacturer's recommended induction phase of treatment.
Methods: Fifty-four treatment-recalcitrant patients (60 eyes) were recruited. OCT and SS-OCTA images were obtained at 0 and 3 months.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!